J.P. Morgan Healthcare Conference

Thursday 7th January 2021

Join McDermott Will & Emery and EY at the 2021 J.P. Morgan Healthcare Conference

Please join us for unparalleled dealmaking opportunities, “need-to-know” trends and unique networking events spanning across two weeks. Our annual event, now virtual, will help you develop an effective, long-term strategy through the post-pandemic period and provide you an unmatched industry experience.

McDermott and EY will present a robust program featuring industry leaders to address implications faced by investors upended by COVID-19 and dynamic topics in healthcare acquisition and financing, joint ventures and collaborations.

7, 11–13 January 2021
Times vary by day
*Registration for all events is complimentary

REGISTER TODAY

Digital Health
Thursday, 7 January

12:00 p.m.–2:00 p.m. EST

Join top industry executives for a series of fireside chats on the evolving doctor-patient relationship and the digitized data and technology convergence with healthcare delivery and payment. Gain insight into 2021’s regulatory considerations affecting healthcare innovation and its solutions.

Life Sciences Investment Forum
Monday, 11 January

Biopharma
10:00 a.m.–11:00 a.m. EST

MedTech
11:00 a.m.–12:00 p.m. EST

Cell and Gene Therapies
12:00 p.m.–1:00 p.m. EST

Mergers & acquisitions (M&A) leaders from across the industry will discuss the current state of biopharma and medtech dealmaking. For biopharma, with the power of new technologies, from antibody drug conjugates in oncology to RNA-based vaccines, these new innovations sparked many of 2020’s most notable deals and are sure to be important in the future. For medtech, with global hospital utilizations continuing to improve month over month and (hopefully) more visibility into 2021 operating results, the medtech M&A market could be poised for a decent rebound and increase going into 2021.

We will also discuss, in a separate panel of cell and gene therapy stakeholders from life sciences, health care, payor, technology and other collaborators, how the future of the CGT industry is evolving to more digitally enhanced business models with collaboration and information sharing at the center of its success.

Healthcare Private Equity Leaders Forum
Tuesday, 12 January

12:00 p.m.–2:00 p.m. EST

Our series of panels with senior private equity professionals and bankers in the healthcare services industry will provide perspective on topics that include:

The macroeconomic outlook and the potential rebound implications for 2021

An analysis of the election, its policy implications, the legislative agenda and the resulting impact to PE

The explosive rise of Special purpose acquisition company (SPAC) transactions in 2020

The growing trend of increased interest from PE in hospitals and health systems, and potential innovative partnerships and creative deals that we may see going forward

Hospital & Health Systems
Wednesday, 13 January

State of the Market
12:00 p.m.–12:20 p.m. EST

CEO Panel: Strategic Business Priorities
12:20 p.m.–1:10 p.m. EST

Legal and Financial Trends
1:10 p.m.–2:00 p.m. EST

Leading professionals will discuss developing trends and how to position your organization to innovate, collaborate and grow in this dynamic environment, where today’s hospitals and health systems face unprecedented levels of disruption. New this year, hear from prominent health system Chief Executive Officers as they share their strategic business priorities for 2021 and beyond, during our CEO panel.

Business Development (led by Deborah O’Neil of NovaBiotics)

enables members to tap into the expertise of other, often larger, member companies, and to develop collaborative solutions to issues facing the sector as a whole.

Finance (led by Hugh Griffith of Nucana BioMed and Alida Capital)

has focussed on the availability of venture capital funding, but also looks at the provision of public sector support for our member companies. Also coordinates the Innovation Tutorial Programme.

HR (led by Fiona Beattie of IQVIA)

is valued by our members as a forum where HR and recruitment issues can be discussed in a collaborative space and pragmatic solutions developed with the secondary and tertiary education sectors.

Diagnostics and MedTech (led by Colin King of Omega Diagnostics Group PLC)

tackles issues of particular relevance to diagnostics companies as they arise, and has also produced a summary of the opportunities for and barriers to growth in the diagnostics sub-sector of life sciences.

Innovation (led by David Pritchard, Axis-Shield, and Douglas Drysdale, HGF)

covers a variety of issues including ownership and commercialisation of University IP through to tax incentives for innovation.

Regulatory and Quality (led by Andrew Waddell of TMQA)

is a forum for SLA members to learn about the regulatory and compliance issues affecting product development and commercialisation, and make representations to regulators and Government as needed. Currently, SLA representatives sit on three MHRA panels.

Digital Health (led by Campbell Grant of Sitekit Solutions)

enables collaboration between member companies in this expanding area, covering personal health software development, telehealthcare systems implementation, health data mining, and life sciences risk analysis systems; and works to help grow companies in this part of the life sciences sector

Cell Therapy (led by Jim Reid of Sistemic)

aims to be a strong industry voice for the stem cell community in Scotland; and makes investors and Government aware of the timeline and costs associated with developing an industry in the sector.

Medicines (led by Tom Stratford of ProStrakan)

works closely with the Scottish Government as it sets up a new partnership between medicine development companies in Scotland and the NHS

Directors Forum (led by Alan Walker of Ryboquin)

provides a space for both Executive and Non-Executive Directors of member companies to meet and exchange views on the sector in Scotland, and to be briefed on hot topics.

Manufacturing (led by John Scott of JnJ)

aims to highlight opportunities for investment in, and benefits of automation, along with pitfalls, challenges and best practice.

Precision Medicine (led by David Bunton of Reprocell)

is focused on getting the most from the recent government investment in the Stratified Medicines Innovation Centre. It aims to bring together SMS-IC with Scottish life sciences companies, and to facilitate cross-company collaborations.

Japan SIG (led by Ken Sutherland of Canon Medical Research Europe Ltd)

is focused on developing the relationship between member companies and Japan, particularly Japanese owned companies based in Scotland.

The voice of Scotland's life sciences industries

J.P. Morgan Healthcare Conference

Thursday 7th January 2021